120 related articles for article (PubMed ID: 31252305)
1. Light-controlled inhibition of BRAFV600E kinase.
Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
[TBL] [Abstract][Full Text] [Related]
2. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
3. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
4. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
[TBL] [Abstract][Full Text] [Related]
5. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
Aldaghi SA; Jalal R
Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
7.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
[TBL] [Abstract][Full Text] [Related]
9. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells.
Ramisetti SR; Pandey MK; Lee SY; Karelia D; Narayan S; Amin S; Sharma AK
Eur J Med Chem; 2018 Jan; 143():1919-1930. PubMed ID: 29133035
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
Li QS; Li CY; Lu X; Zhang H; Zhu HL
Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
15. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
[TBL] [Abstract][Full Text] [Related]
16. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
19. A Fluoro Derivative of Embelin, as Potent B-RAF Inhibitor in Melanoma.
Babu A; Laila SP; Fernandez A
Anticancer Agents Med Chem; 2021; 21(15):2066-2074. PubMed ID: 33372883
[TBL] [Abstract][Full Text] [Related]
20. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
Walter L; Heinzerling L
Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
